Screener
Bristol-Myers Squibb BMY EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
FAQ
- What is Bristol-Myers Squibb's EBITDA?
- Bristol-Myers Squibb (BMY) reported EBITDA of $4.68B in Q2 2026.
- How has Bristol-Myers Squibb's EBITDA changed year-over-year?
- Bristol-Myers Squibb's EBITDA increased by 68.1% year-over-year, from $2.78B to $4.68B.
- What is the long-term trend for Bristol-Myers Squibb's EBITDA?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's EBITDA has grown at a -8.2% compound annual growth rate (CAGR), from $18.78B to $13.34B.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Bristol-Myers Squibb's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude